Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WNT3A | P56704 | 7/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 4/20 | 0.36 |
| ▸ | GSK3B | P49841 | 2/20 | 0.35 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17778461 | 1.00 | WNT3A (0.38) | WNT3AABL1IRAK4FAAHGRM5 | |
| SCHEMBL17778459 | 0.90 | GSK3B (0.38) | FAAHGRM5GSK3BDYRK1ATRPV1 | |
| SCHEMBL17769524 | 0.89 | GRM5 (0.36) | IRAK4FAAHGRM5GSK3BDYRK1A | |
| SCHEMBL17618509 | 0.87 | WNT3A (0.41) | WNT3AABL1FAAHGRM5GSK3B | |
| SCHEMBL19689674 | 0.86 | WNT3A (0.41) | WNT3AGSK3BMAPK1 | |
| SCHEMBL17778224 | 0.86 | WNT3A (0.41) | WNT3AGSK3BMAPK1 | |
| SCHEMBL17778364 | 0.86 | FAAH (0.38) | WNT3AABL1FAAHGRM5MAP3K12 | |
| SCHEMBL17778460 | 0.86 | MTOR (0.42) | — | |
| SCHEMBL17778718 | 0.86 | MAPK1 (0.38) | WNT3AMAPK1 | |
| SCHEMBL17767922 | 0.86 | MAPK1 (0.38) | WNT3AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180319810-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2018-11-08 | — | — | US | disclosed |
| EP-3220918-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2017-09-27 | — | — | EP | disclosed |
| WO-2016079712-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180319810-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | WNT3A 4543/4885ABL1 3763/4885IRAK4 2915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.